A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants

ConditionHealthy Participants

Trial statusNot yet recruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18-55

SponsorZhejiang Wenda Pharma Technology LTD.

About this trial

This is a phase I, randomised, double-blind, placebo-controlled, 3-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of WD-910 in in Healthy Participants Detailed

Eligibility criteria

Qualifiers

Aged 18 to 55 years (inclusive) at the time of informed consent.

Body mass index (BMI) between 18 to 32 kg/m2 and male participant with body weight of ≥ 50.0 kg, female participant with body weight ≥ 45.0 kg

Disqualifiers

Any major surgery within 12 weeks prior to Day 1, or any planned surgery during the study.

Poor pill swallowing ability

Trial design

Treatments tested in this trial

WD-910 tablet
WD-910 Tablets Placebo

Treatment groups

68 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Zhejiang Wenda Pharma Technology LTD.

Lead sponsor

Source ClinicalTrials.gov